Direx debuts low-field MR at ECR show

Article

Urology equipment manufacturer Direx Medical Systems is planning to enter the MR market withMarex, a low-field magnet shown for the first time at this month'sEuropean Congress of Radiology meeting in Vienna. Marex is a 0.1-tesla permanent magnet

Urology equipment manufacturer Direx Medical Systems is planning to enter the MR market withMarex, a low-field magnet shown for the first time at this month'sEuropean Congress of Radiology meeting in Vienna.

Marex is a 0.1-tesla permanent magnet vertical-field systemwhose appearance bears a passing resemblance to Toshiba's 0.064-teslaAccess magnet. Direx is positioning the system as a low-cost scannerfor the private clinic market in Western countries as well asa secondary unit for public-sector hospitals. The system is alsowell suited for markets in developing countries, according toRon Shifron, director of marketing for Direx, which is based inPetah-Tikva, Israel.

Marex is capable of imaging about 85% of the body and employs10-mtesla/meter gradients. It weighs 2.5 tons, sites in 16 squaremeters and requires neither floor reinforcement nor special magneticshielding. Its power consumption is low enough to enable the useof a regular wall outlet. The scanner also features a detachabletable, which enables users to prepare one patient while anotheris being imaged.

Direx believes there is room in the market for a system likeMarex despite the global plunge in MRI sales. High-field systemshave been most affected by the dropping market, according to Shifron.

"We feel that in this niche market there is still roomfor this kind of machine," Shifron said. "The impressionI'm getting from this meeting is that the low-field market iscoming up and about, even within Europe, where they have had aproblem recognizing the low-field scanners due to all the governmentregulations."

Direx plans to sell Marex for about $400,000 to $500,000 andwill market the system directly where possible through its networkof 10 offices worldwide, with agents responsible for other markets.Direx is in the process of applying for regulatory clearancesto sell the system.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.